Gastrointestinal Cancer

胃肠癌

基本信息

批准号：
9282706
负责人：
KAREN E KNUDSEN
金额：
$ 3.83万
依托单位：
THOMAS JEFFERSON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-06-01 至 2018-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9282706
关键词：
Adjuvant Therapy Biological Markers Cancer Biology Cancer Center Cancer Control Chemoprevention Clinical Clinical Trials Clinical Trials Design Collaborations Colorectal Cancer Diagnosis Diagnostic Diagnostic Trial Disease Early Diagnosis Enrollment Epigenetic Process Evidence based practice Family Practice Funding Goals Healthcare Systems Hormones Immunotherapeutic agent In Vitro Inflammation Instruction Internal Medicine Intestines Laboratories Malignant Neoplasms Malignant neoplasm of esophagus Malignant neoplasm of gastrointestinal tract Malignant neoplasm of liver Malignant neoplasm of pancreas Medical Oncology Micronutrients Modality Molecular Molecular Genetics Neoplasm Metastasis Neoplasms Operative Surgical Procedures Organ Paper Pathology Patients Peer Review Pharmacology Population Postoperative Period Prevention Process Publications Publishing Radiology Specialty Research Research Personnel Risk stratification Role Scientist Staging Stem cells Therapeutic Therapeutic Trials Translating Translational Research Translations Universities Work base cancer chemoprevention cancer prevention clinical application clinical development cohesion gastrointestinal improved in vivo individual patient innovation medical schools member molecular targeted therapies multidisciplinary novel novel diagnostics novel therapeutics outcome forecast paracrine patient population predictive marker prevent prognostic programs racial disparity tool tumorigenesis

项目摘要

PROJECT SUMMARY (See Instructions): The Gastrointestinal (Gl) Cancer Program (Program #6), one of the original programs of the Kimmel Cancer Center at Jefferson, is a multidisciplinary program composed of 25 full and 5 associate members representing 8 departments within Jefferson Medical College (Pathology; Cancer Biology; Family Medicine; Internal Medicine; Medical Oncology; Pharmacology; Radiology; Surgery), the Christiana Care Health System (Helen F. Graham Cancer Center), and Drexel University, whose over-arching goal is to define fundamental mechanisms underlying Gl malignancies which can be translated into diagnostic and therapeutic innovations for managing cancer in patients and populations. Their work is supported by �~$7.7M in peer-reviewed funding, representing an increase of -75% from $4.4M during the past funding period. Also, program members have published 561 papers, representing almost a doubling compared to the previous funding period. Of those, >17% were intra-programmatic, representing a tripling of the previous rate, and >16% were inter-programmatic. Program members pursue parallel efforts organized along organ based disease processes from discovery through translation to clinical development and application. Members employ common and collaborative experimental paradigms with the goals of (1) defining previously unappreciated molecular, genetic, and epigenetic mechanisms underlying Gl organ-based tumorigenesis, (2) translating defined mechanisms into novel in vitro and in vivo tools to improve prevention, early detection, prognosis, prediction, and risk-stratification in Gl malignancies, (3) defining molecularly targeted therapeutic approaches for cancer prevention, treatment, and control, (4) advancing novel laboratory discoveries into development for clinical trials, and (5) advancing clinically successful diagnostic and therapeutic trials into evidence-based practice for cancer prevention and control across populations. In that context, enrollment of patients in Gl cancer-based clinical trials has increased ~15-fold compared to the past funding period. Members are interactive and cohesive and, under the direction of Program Leaders, coordinate research planning and new research directions with other research programs in the Cancer Center.

项目摘要（请参阅说明）：杰斐逊金梅尔癌症中心的原始计划之一是胃肠道（GL）癌症计划（计划＃6），是一个多学科计划，由25个完整的和5名代表杰斐逊医学院内8个部门（癌症生物学；癌症生物学；家庭医学;家庭医学；内科医学;医疗学中心; carragology; carrenagy; carrencer and crander and ofer carry carry Systems）组成，癌症医学中心；大学，其超大目标是定义 GL恶性肿瘤的基本机制可以转化为用于管理患者和人群癌症的诊断和治疗创新。他们的工作得到了约770万美元的同行评审资金的支持，在过去的资金期间，从440万美元增加了-75％。此外，计划成员发表了561篇论文，与以前的资金期相比几乎翻了一番。其中，> 17％是概括性的，代表上一个率的三倍，> 16％是策略间的。计划成员购买沿基于器官的疾病过程组织的并行努力，从发现到临床开发和应用。会员员工的员工常见和协作实验范式的目标是（1）定义先前未经批准的分子，遗传和表观遗传学机制，基于GL器官的肿瘤发生的基础，（2）将定义的机制转化为新颖的体外和体内工具，以改善预防，预测，预测，预测和摩尔（GLEC），并在PLECTICT，预测和风险中（GLEC），（3）（4）（4）将新颖的实验室发现推进临床试验的发展，以及（5）将临床成功的诊断和治疗试验推进到基于循证的基于循证的预防和控制人群的癌症实践中。在这种情况下，与过去的融资期相比，基于GL癌症的临床试验的患者入学率增加了约15倍。成员具有互动性和凝聚力，在计划负责人的指导下，与癌症中心的其他研究计划进行协调研究计划和新的研究指示。